Kisplyx Unione Europea - italiano - EMA (European Medicines Agency)

kisplyx

eisai gmbh - lenvatinib mesilato - carcinoma, cellule renali - agenti antineoplastici - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

PROMUS ELEMENT PLUS MONORAIL BTK EVEROLIMUS-ELUTING STENT SYSTEM Italia - italiano - Ministero della Salute

promus element plus monorail btk everolimus-eluting stent system

boston scientific corporation - stent vascolari periferici a cessione di farmaco (des)

PROMUS ELEMENT PLUS OVER-THE-WIRE BTK EVEROLIMUS-ELUTING STENT SYSTEM Italia - italiano - Ministero della Salute

promus element plus over-the-wire btk everolimus-eluting stent system

boston scientific corporation - stent vascolari periferici a cessione di farmaco (des)

XIENCE V EVEROLIMUS ELUTING CORONARY STENT SYSTEM Italia - italiano - Ministero della Salute

xience v everolimus eluting coronary stent system

abbott vascular, cardiac therapies - stent coronarici a cessione di farmaco (des)

XIENCE V EVEROLIMUS ELUTING CORONARY STENT SYSTEM Italia - italiano - Ministero della Salute

xience v everolimus eluting coronary stent system

abbott vascular, cardiac therapies - stent coronarici a cessione di farmaco (des)

XIENCE PRIME EVEROLIMUS ELUTING CORONARY STENT SYSTEM Italia - italiano - Ministero della Salute

xience prime everolimus eluting coronary stent system

abbott vascular inc. - stent coronarici a cessione di farmaco (des)